
Opinion|Videos|April 4, 2025
Evaluating Five-Year Efficacy Outcomes in EMPOWER-LUNG 1
Author(s)Eric K. Singhi, M.D., Ben Creelan, M.D.
Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival (PFS). Cemiplimab’s outcomes align well with other PD-1/PD-L1 inhibitors, influencing clinical decisions for its use as a first-line treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the current five-year prognosis for advanced NSCLC in terms of overall survival and progression-free survival?
- How do the reported OS and PFS outcomes compare with other PD-1/PD-L1 inhibitors in the setting of advanced NSCLC?
- How does this new five-year data impact clinical decision-making for cemiplimab as a first-line treatment for patients with advanced NSCLC?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
PBM reform. It has finally happened
3
TrumpRx launches; some experts question its long-term value
4
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
5



























